3-hydroxy-1-methoxy-9H-xanthen-9-one | 41534-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-hydroxy-1-methoxy-9H-xanthen-9-one
• 英文别名: 3-hydroxy-1-methoxy-xanthen-9-one；3-Hydroxy-1-methoxy-xanthon；1-Methoxy-3-hydroxyxanthon；3-hydroxy-1-methoxyxanthen-9-one
• CAS: 41534-46-7
• 化学式: C₁₄H₁₀O₄
• 分子量: 242.231
• InChiKey: AFMFXCSDELCPHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-hydroxy-1-methoxy-9H-xanthen-9-one 在 盐酸 、 potassium carbonate 作用下， 以 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.5h， 生成 3-(3-chloro-2-hydroxypropoxy)-1-methoxy-9H-xanthen-9-one
  参考文献：
  名称：

  NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME

  摘要：

  本发明提供了一种新型黄酮衍生物化合物或其药用可接受盐。该化合物可用作化疗增敏剂，可降低抗癌药物的耐药性。

  公开号：

  US20120190724A1
• 作为产物：
  描述：

  1,3-二羟基氧杂蒽-9-酮 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 caesium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 50.0~60.0 ℃ 、344.75 kPa 条件下， 反应 39.0h， 生成 3-hydroxy-1-methoxy-9H-xanthen-9-one
  参考文献：
  名称：

  NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME

  摘要：

  本发明提供了一种新型黄酮衍生物化合物或其药用可接受盐。该化合物可用作化疗增敏剂，可降低抗癌药物的耐药性。

  公开号：

  US20120190724A1

文献信息

• Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues
  作者：Sangwook Woo、Da-hye Kang、Jung Min Nam、Chong Soon Lee、Eun-Mi Ha、Eung-Seok Lee、Youngjoo Kwon、Younghwa Na

  DOI：10.1016/j.ejmech.2010.06.017

  日期：2010.9

  etoposide at 100 μM concentration. In the DNA cross-linking test, compounds 20, 30 and 31 produced DNA cross-linked adducts and compound 30 was the strongest DNA cross-linker. Based on the combined pharmacological results, we suspected that the strong anti-cancer activity of compounds 16, 17, 20, 30 and 31 originated from the DNA mono-alkylation or cross-linking properties of the compounds.

  为了开发对拓扑异构酶II和DNA起作用的潜在抗癌药，我们合成了12种新的黄酮酮衍生物。在细胞毒性测试中，化合物17和31对大多数测试的癌细胞系的抑制活性比阿霉素强2至7倍。卤代醇基团拴化合物19，21和27显示出相当的拓扑异构酶II依托泊苷抑制活性，在100μM浓度。在DNA交联测试中，化合物20，30和31产生的DNA交联的加合物和化合物30是最强的DNA交联剂。基于组合的药理学结果，我们怀疑化合物的强的抗肿瘤活性16，17，20，30和31源自所述化合物的DNA的单烷基化或交联性能。
• Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same
  申请人：Na Young Hwa

  公开号：US08846749B2

  公开（公告）日：2014-09-30

  The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.

  本发明提供了一种新型黄酮衍生物化合物或其药学上可接受的盐。该化合物可用作化疗增敏剂，可减少抗癌药物的耐药性。
• Anti-AIDS agents 89. Identification of DCX derivatives as anti-HIV and chemosensitizing dual function agents to overcome P-gp-mediated drug resistance for AIDS therapy
  作者：Ting Zhou、Emika Ohkoshi、Qian Shi、Kenneth F. Bastow、Kuo-Hsiung Lee

  DOI：10.1016/j.bmcl.2012.03.037

  日期：2012.5

  In this study, 19 dicamphanoyl-dihydropyranochromone (DCP) and dicamphanoyl-dihydropyranoxanth-one (DCX) derivatives, previously discovered as novel anti-HIV agents, were evaluated for their potential to reverse multi-drug resistance (MDR) in a cancer cell line over-expressing P-glycoprotein (P-gp). Seven compounds fully reversed resistance to vincristine (VCR) at 4 mu M, a 20-fold enhancement compared to the first generation chemosensitizer, verapamil (4 mu M). The mechanism of action of DCPs and DCXs was also resolved, since the most active compounds (3, 4, and 7) significantly increased intracellular drug accumulation due, in part, to inhibiting the P-gp mediated drug efflux from cells. We conclude that DCPs (3 and 4) and DCXs (7, 11, and 17) can exhibit polypharmacologic behavior by acting as dual inhibitors of HIV replication and chemoresistance mediated by P-gp. As such, they may be useful in combination therapy to overcome P-gp-associated drug resistance for AIDS treatment. (C) 2012 Elsevier Ltd. All rights reserved.
• Rutaceous constituents—13
  作者：Joyce H. Adams、P. Margaret Brown、the late Padma Gupta、M. Shafig Khan、John R. Lewis

  DOI：10.1016/s0040-4020(01)97737-3

  日期：1981.1
• US8846749B2
  申请人：——

  公开号：US8846749B2

  公开（公告）日：2014-09-30